CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 486 enrolled
Drug / intervention
Ivermectin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02795117
NCT02795117Phase 3Completed
CompareCT.gov

Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea

Padagis LLC·interventional·Posted Jun 9, 2016·Updated Nov 2, 2021

In Brief

A Phase 3 clinical trial evaluating Ivermectin, Ivermectin (reference), and 1 other intervention for Rosacea. Completed, enrolled 486 participants.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 9, 2016
Enrollment StartMay 1, 2016
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.1 years ago

Interventions

Ivermectindrug

Ivermectin (reference)drug

Placebodrug